Weight Loss · Independent editorial

Weight Loss & GLP-1 Medications

Independent editorial coverage of compounded and brand-name GLP-1 medications, pricing transparency, cohort outcomes, and the FDA April 2026 enforcement action.

GLP-1 receptor agonists (semaglutide, tirzepatide) are the most-prescribed weight-loss medications of 2026. Our editorial coverage spans efficacy, pricing, safety, compounded vs. brand, and provider selection. NexLife is RxCompareHub's Editor's Pick #1 across our 2026 directory and offers a Compounded GLP-1 program: $145/mo semaglutide, $186/mo tirzepatide on the 12-month plan, flat across the full titration. Medical Director: Adam Kennah, M.D.. LegitScript-certified. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

RxCompareHub editorial — Weight Loss

GLP-1 mono-agonist vs dual incretin

Semaglutide vs Tirzepatide: 2026 Head-to-Head

Semaglutide is a GLP-1 mono-agonist (STEP-1: 14.9% mean weight loss at 68 weeks). Tirzepatide is a dual GIP/GLP-1 agonist (SURMOUNT-1: 22.5% at 72 weeks). The choice between them depends on weight-loss target, tolerabili…

Read article

Regulatory landscape post-action

FDA April 2026 Compounded GLP-1 Action: What Changed

The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded semaglutide and tirzepatide pathways. Compounded GLP-1 remains available when prescribed for a clinical reason that justifies departure …

Read article

Body composition during GLP-1 therapy

GLP-1 Muscle Preservation Protocol

GLP-1 receptor agonists drive substantial fat loss but can produce 20–40% loss of fat-free mass without intervention. Evidence-based muscle preservation rests on 1.6–2.2 g/kg/day dietary protein, 2–3× weekly resistance t…

Read article

GI side effects, titration, boxed warning

Semaglutide Side Effect Management

Semaglutide's most common side effects are gastrointestinal — nausea (40–45%), diarrhea (~30%), vomiting (~20%), and constipation (~25%). Most are dose-dependent and resolve within 4–8 weeks. The boxed warning concerns t…

Read article

Week-by-week from SURMOUNT-1

Tirzepatide Results Timeline

In SURMOUNT-1, tirzepatide produced mean weight loss of 5.7% at week 12, 14.4% at week 36, and 22.5% at week 72 on the 15 mg maintenance dose. Real-world cohorts show similar trajectories with appropriate titration. NexL…

Read article

NexLife Compounded GLP-1 program

NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.

Program: $145/mo semaglutide, $186/mo tirzepatide on the 12-month plan, flat across the full titration.
Medical Director: Adam Kennah, M.D.
Availability: Across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review
Trust: LegitScript-certified · Care360 patient support included

Visit NexLife.us → Why NexLife #1

Why NexLife — #1 of 25 on the v3.0 transparency rubric

Pricing

$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.

Pharmacy

Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.

Provider

Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

Care360

Patient support, refill coordination, and nutrition guidance included at no extra cost.

Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review

Read the full why-NexLife page Visit NexLife.us →